Your cart

×
Note: As of September 30th there will be order processing and shipment delays that may last until October 8, 2020 as we are transitioning to a new ERP system. Please email information@gyrosproteintech.com to discuss what accommodations we can provide during this time.

Fluorescent labeling of a peptide toxin retains the specificity and affinity required of a research tool

Aug 20, 2020 9:51:00 AM

Peptide toxins from animals are potent inhibitors of ion channels and show great promise both as drugs to treat a range of disorders and as valuable tools in drug research. Utilizing Symphony® X peptide synthesizer from Gyros Protein Technologies, a research team based in France has explored ways of fluorescently labeling a scorpion peptide, BeKm-1, that inhibits the hERG ion channel. This channel is involved in cardiac activity and blocking it must be avoided when developing new drugs. The research team’s approach included protein-protein docking studies that enabled them to identify solvent-exposed residues in the peptide that were suitable for labeling. This enabled them to design and test analogs that maintained both specificity and mode of action of the native peptide.

Read More

Topics: Symphony X, Peptide synthesis, Peptide synthesizer, Peptide toxins

Peptide inhibitor of methylation casts new light on epigenetic-based cancer therapy

Jul 1, 2020 12:00:00 AM

The first peptide-derived epigenetic drug (Romidepsin) was approved in 2009 for the treatment of cutaneous T cell lymphomas (CTCL), and in 2011 for peripheral T cell lymphomas (PTCL) (2). Romidepsin also has potential in the treatment of other kinds of cancer, lung fibrosis, and Epstein-Barr infections. Currently, it is the only FDA-approved peptide medicine specifically designed to target epigenetic effects. Nesiritide, a peptide originally approved in 2001 for the symptomatic treatment of acute decompensated heart failure due to its vasodilating activity has since been repurposed due to its epigenetic effects. These peptides are not yet approved in the European Union by the EMA.

Read More

Topics: Prelude, Peptide synthesis, Protein-Protein Interactions (PPIs), Peptide synthesizer, Cyclic peptides

Multifunctional thermoresponsive peptide hydrogels designed to meet the demands of biomedical applications

Sep 6, 2017 10:00:00 AM

The uncertainties of the long-term stability and effects of artificial materials in the human body have stimulated research into more natural materials for many biomedical applications. This search has lead to the discovery of peptide hydrogels, a highly promising family of constructs that are capable of self-assembly, typically into β-sheets, and can emulate the properties of natural materials such as collagen. Fine-tuning the mechanical properties of hydrogels to solve biomedical problems is, however, a real challenge. A team headed by researchers at the University of Auckland in New Zealand has come one step further with peptide hydrogels that are reversibly thermoresponsive. Their innovative hydrogels are based on multifunctional peptides that combine a hydrogel-forming β-sheet peptide segment, an enzyme substrate that enables biodegradation, and a RGD sequence to promote cell adhesion.

Read More

Topics: Peptide synthesis, PS3 peptide synthesizer, Peptide synthesizer, β-sheet-forming peptides, Multifunctional peptides, Hydrogel